NEW YORK, Jan 29 – Sequitir said Monday it signed a multi-year, multi-million dollar deal to supply Bristol-Myers Squibb with its antisense compounds for target validation and to perform biological screening for the pharmaceutical company.
Already have a GenomeWeb or 360Dx account?Login Now.
The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.
A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.
Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.
In Science this week: analysis of DNA from ancient North Africans, and more.